| Not Yet Recruiting | Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP NCT07354074 | Novartis Pharmaceuticals | Phase 2 |
| Not Yet Recruiting | TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients NCT07489755 | Shenzhen TargetRx Co., Ltd. | Phase 3 |
| Recruiting | ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis NCT06680661 | Leland Metheny | Phase 2 |
| Not Yet Recruiting | A Clinical Trial to Evaluate the Safety and Tolerability of TQB3911 Tablets in Patients With BCR::ABL Fusion G NCT06672263 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 1 |
| Not Yet Recruiting | Study of HS-10382 Combination in Patients With Chronic Myeloid Leukemia (CML) NCT06530810 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia NCT06088888 | Shenzhen TargetRx Co., Ltd. | Phase 1 |
| Unknown | The Evaluation and Comparison of BCR-ABL p210 mRNA Transcripts (%IS Unit) Results Between Dr. PCR™ BCR-ABL1 Ma NCT06301321 | Siriraj Hospital | — |
| Recruiting | Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution NCT06131801 | Children's Hospital Medical Center, Cincinnati | — |
| Recruiting | Allo HSCT Using RIC and PTCy for Hematological Diseases NCT05805605 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Withdrawn | CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies NCT04282174 | Baptist Health South Florida | Phase 2 |
| Recruiting | Asciminib Roll-over Study NCT04877522 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Asciminib Treatment Optimization in ≥ 3rd Line CML-CP NCT04948333 | Novartis Pharmaceuticals | Phase 3 |
| Active Not Recruiting | HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide NCT04904588 | Center for International Blood and Marrow Transplant Research | Phase 2 |
| Recruiting | Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft NCT05088356 | Stanford University | Phase 1 |
| Active Not Recruiting | TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients NCT05434312 | Shenzhen TargetRx Co., Ltd. | Phase 1 |
| Unknown | Methods of T Cell Depletion Trial (MoTD) NCT04888741 | University of Birmingham | Phase 2 |
| Completed | Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy NCT04014764 | Notable Labs | — |
| Completed | Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies NCT04191187 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Active Not Recruiting | Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy NCT03674411 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukem NCT03578367 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leu NCT03625388 | Hikma Pharmaceuticals LLC | Phase 2 |
| Recruiting | Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders NCT03314974 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More T NCT03106779 | Novartis Pharmaceuticals | Phase 3 |
| Completed | UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep NCT02722668 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Withdrawn | StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies NCT02765997 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | Allo HSCT Using RIC for Hematological Diseases NCT02661035 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Terminated | Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies NCT02991898 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies NCT02743351 | Fate Therapeutics | Phase 1 / Phase 2 |
| Recruiting | Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases NCT01962636 | Masonic Cancer Center, University of Minnesota | N/A |
| Completed | Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine NCT02996773 | University of Arizona | Phase 1 |
| Terminated | Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Le NCT02709083 | Emory University | Phase 2 |
| Unknown | Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia NCT03216070 | Hospital Universitario Dr. Jose E. Gonzalez | Phase 4 |
| Completed | Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplan NCT02639559 | Washington University School of Medicine | Phase 2 |
| Completed | Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis NCT02593123 | Virginia Commonwealth University | Phase 2 |
| Completed | Reduced Intensity Conditioning Transplant Using Haploidentical Donors NCT02581007 | Northside Hospital, Inc. | Phase 2 |
| Completed | Cognitive Behavioral Intervention for Targeted Therapy Fatigue (CBT-TTF) Intervention NCT02592447 | H. Lee Moffitt Cancer Center and Research Institute | N/A |
| Completed | Intra-Osseous Co-Transplant of UCB and hMSC NCT02181478 | Case Comprehensive Cancer Center | EARLY_Phase 1 |
| Completed | Safety And Efficacy Of Bosutinib NCT02501330 | Pfizer | — |
| Unknown | Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood He NCT02338479 | Center for International Blood and Marrow Transplant Research | — |
| Completed | Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies NCT02566395 | Northwell Health | Phase 3 |
| Terminated | Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases NCT02145039 | Masonic Cancer Center, University of Minnesota | N/A |
| Completed | Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) NCT02208037 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Completed | Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention NCT01951885 | Case Comprehensive Cancer Center | Phase 3 |
| Completed | A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL NCT02081378 | Novartis Pharmaceuticals | Phase 1 |
| Terminated | Evaluating the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Chronic Myelogenous Leu NCT02047149 | University of Massachusetts, Worcester | Phase 1 |
| Terminated | AHN-12 Biodistribution in Advanced Leukemia NCT01207076 | Masonic Cancer Center, University of Minnesota | Phase 1 |
| Completed | Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplant NCT01634217 | Masonic Cancer Center, University of Minnesota | Phase 1 |
| Completed | A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor NCT01696461 | Center for International Blood and Marrow Transplant Research | Phase 2 |
| Completed | Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients NCT01784068 | Novartis Pharmaceuticals | Phase 2 |
| Unknown | A Phase II Study to Evaluate the Efficacy and the Safety of Flumatinib in CML-AP or CML-BP Patients NCT02511340 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 2 |
| Unknown | Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission NCT01901666 | Post Graduate Institute of Medical Education and Research, Chandigarh | Phase 4 |
| Completed | Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating NCT01690520 | Nohla Therapeutics, Inc. | Phase 2 |
| Suspended | Phase III Study of Compound Formula Realgar-Indigo Naturalis Plus Imatinib Versus Placebo Plus Imatinib in Adu NCT01755325 | Junmin Li | Phase 3 |
| Terminated | Population Pharmacokinetics of Imatinib in CML Patients in Iran NCT02146846 | Kerman University of Medical Sciences | — |
| Completed | Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell NCT01660607 | Stanford University | Phase 1 / Phase 2 |
| Completed | Improving Blood Stem Cell Collection and Transplant Procedures NCT01517035 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 1 / Phase 2 |
| Completed | Safety and Tolerability of HSC835 in Patients With Hematological Malignancies NCT01474681 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Unknown | Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia NCT01513603 | New York Medical College | Phase 2 |
| Completed | Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG NCT01390402 | M.D. Anderson Cancer Center | Phase 2 |
| Withdrawn | Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy NCT01452334 | Bristol-Myers Squibb | Phase 1 |
| Active Not Recruiting | Administration of Donor T Cells With the Caspase-9 Suicide Gene NCT01494103 | Baylor College of Medicine | Phase 1 |
| Terminated | Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell NCT01500161 | Texas Oncology Cancer Center | Phase 2 |
| Terminated | Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML) NCT01397734 | Beth Israel Deaconess Medical Center | Phase 1 |
| Completed | Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation NCT01338987 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation NCT01326728 | National Cancer Institute (NCI) | — |
| Completed | Nilotinib + Pegylated Interferon Alpha 2a for Untreated Chronic Phase Chronic Myelogenous Leukemia NCT01294618 | Hospices Civils de Lyon | Phase 2 |
| Completed | Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia NCT01484015 | Wake Forest University Health Sciences | Phase 1 |
| Completed | Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukem NCT01274351 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenou NCT01316250 | American University of Beirut Medical Center | N/A |
| Terminated | Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation NCT01366612 | Hackensack Meridian Health | Phase 3 |
| Completed | Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias NCT01149915 | Threshold Pharmaceuticals | Phase 1 |
| Completed | Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic S NCT01075425 | Virginia Commonwealth University | Phase 1 |
| Completed | ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies NCT01110473 | AbbVie (prior sponsor, Abbott) | Phase 1 |
| Terminated | Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML. NCT01130688 | University of Massachusetts, Worcester | Phase 1 |
| Completed | An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Trea NCT00980018 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Ondansetron Versus Aprepitant Plus Ondansetron for Emesis NCT00954941 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or R NCT00990587 | University Health Network, Toronto | Phase 1 |
| Completed | A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for NCT01036009 | University of California, San Francisco | Phase 2 |
| Completed | Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloa NCT00975975 | Indiana University School of Medicine | Phase 2 |
| Withdrawn | A Study of Imatinib and Valproic Acid in Patients With Chronic Myelogenous Leukemia (CML) NCT01011998 | New Mexico Cancer Research Alliance | Phase 2 |
| Completed | Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Re NCT00760877 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response NCT00802841 | Novartis Pharmaceuticals | Phase 3 |
| Completed | A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies NCT00807677 | Millennium Pharmaceuticals, Inc. | Phase 1 |
| Completed | Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid L NCT01368523 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematolo NCT00739141 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies NCT00719836 | S*BIO | Phase 1 / Phase 2 |
| Completed | Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT NCT00709592 | Virginia Commonwealth University | Phase 2 |
| Completed | Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer NCT00723099 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies NCT00660920 | Ariad Pharmaceuticals | Phase 1 |
| Completed | INCB018424 in Patients With Advanced Hematologic Malignancies NCT00674479 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR NCT01611298 | Robert Krance | N/A |
| Withdrawn | PR1-Specific Cytotoxic T-Lymphocyte Infusion With Recurrent Chronic Myelogenous Leukemia (CML) After Allogenei NCT00866346 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transp NCT00674427 | University of Pennsylvania | Phase 1 |
| Completed | Study Evaluating SKI-606 (Bosutinib) In Japanese Subjects With Philadelphia Chromosome Positive Leukemias NCT00811070 | Pfizer | Phase 2 |
| Completed | Investigation of the Cylex® ImmuKnow® Assay NCT00569842 | Indiana University School of Medicine | — |
| Terminated | In-Vivo Activated T-Cell Depletion to Prevent GVHD NCT00594308 | Indiana University | N/A |
| Terminated | A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelph NCT00500006 | Merck Sharp & Dohme LLC | Phase 1 |
| Terminated | Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in NCT00852709 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Completed | Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD NCT00539695 | Baylor College of Medicine | Phase 2 |
| Terminated | Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB) NCT00579111 | Baylor College of Medicine | Phase 1 / Phase 2 |
| Terminated | Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation NCT00626626 | Milton S. Hershey Medical Center | Phase 1 / Phase 2 |
| Completed | Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancie NCT00697671 | St. Jude Children's Research Hospital | Phase 1 |
| Terminated | Intraosseous Infusion of Unrelated Cord Blood Grafts NCT00967525 | Emory University | N/A |
| Completed | Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT NCT00412360 | Medical College of Wisconsin | Phase 3 |
| No Longer Available | Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Int NCT00413270 | Novartis Pharmaceuticals | — |
| Terminated | TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients NCT00415909 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Effect of Imatinib on Bone Metabolism in Patients With Chronic Myelogenous Leukemia or Gastrointestinal Stroma NCT00580281 | Memorial Sloan Kettering Cancer Center | N/A |
| Completed | Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants NCT00378534 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Terminated | An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leuk NCT00346632 | Kyowa Kirin, Inc. | Phase 1 |
| Completed | Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HC NCT00285259 | Astellas Pharma Inc | Phase 2 |
| Completed | Rollover Study of BMS-354825 in Patients With CML and Ph+ALL NCT01030718 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Completed | Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies NCT00270881 | Keio University | Phase 1 / Phase 2 |
| Completed | Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients NCT00493181 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS NCT00334074 | Baylor Research Institute | Phase 2 |
| Completed | Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogeno NCT01279473 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases NCT00309842 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan NCT00337454 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Recruiting | Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical NCT00816114 | M.D. Anderson Cancer Center | — |
| Completed | A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL NCT00384228 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies NCT00109707 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chro NCT00171899 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Unrelated Donor Stem Cell Transplantation NCT01364363 | Scripps Health | N/A |
| Completed | Autologous Transplantation for Chronic Myelogenous Leukemia NCT01003054 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia NCT00101647 | Bristol-Myers Squibb | Phase 2 |
| Terminated | Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients Wtih Advanced Hematopo NCT00513318 | University of California, San Francisco | — |
| Completed | PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP NCT00088231 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers NCT00089596 | ViaCell | Phase 1 / Phase 2 |
| Completed | Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myeloge NCT00079313 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Completed | Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec NCT00661180 | Bayer | Phase 2 |
| Completed | A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Re NCT02829775 | Hoffmann-La Roche | Phase 2 / Phase 3 |
| Completed | Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation NCT00144677 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia NCT00081926 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia NCT00047502 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies NCT00514722 | University of California, San Francisco | N/A |
| Completed | Investigation of Clofarabine in Acute Leukemias NCT00098033 | University of Texas | Phase 2 |
| Completed | Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractor NCT00041990 | Astex Pharmaceuticals, Inc. | Phase 2 |
| Completed | Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to I NCT00042003 | Astex Pharmaceuticals, Inc. | Phase 2 |
| Completed | Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to NCT00042016 | Astex Pharmaceuticals, Inc. | Phase 2 |
| Completed | T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies NCT00683046 | University of Chicago | Phase 2 |
| Completed | Nonmyeloablative Allogeneic Transplant NCT01272817 | Scripps Health | N/A |
| Recruiting | The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Trans NCT01890486 | Wake Forest University Health Sciences | — |
| Terminated | CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation NCT00038818 | M.D. Anderson Cancer Center | N/A |
| Withdrawn | Therapy of Relapsed AML With Chemotherapy and Dendritic Cell Activated Lymphocytes NCT00038870 | M.D. Anderson Cancer Center | N/A |
| Completed | Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant NCT00571662 | University of Nebraska | Phase 2 |
| Completed | Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelp NCT00333840 | Novartis Pharmaceuticals | Phase 3 |
| Completed | T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts NCT00368355 | Baylor College of Medicine | Phase 2 |
| Completed | Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies NCT01499147 | University of Illinois at Chicago | N/A |
| Completed | Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow NCT00003838 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Terminated | Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of NCT03547154 | Merck Sharp & Dohme LLC | Phase 2 / Phase 3 |
| Completed | Analysis of Genetic Factors Related to Predisposition and Prognosis of Hematological Malignancies in Israel NCT00159003 | Deborah Rund | — |
| Completed | Peripheral Blood (PB) Versus Bone Marrow (BM) in Allogeneic Stem Cell Transplantation NCT01020175 | European Society for Blood and Marrow Transplantation | Phase 3 |